1 Magnificent S&P 500 Dividend Stock Down 12% to Buy After Its Recent Pullback
- Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.
- 11/11/2024
|
Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role
- PARSIPPANY, N. J.--(BUSINESS WIRE)--ZOETIS APPOINTS JAMIE BRANNAN TO NEWLY CREATED CHIEF COMMERCIAL OFFICER ROLE.
- 11/11/2024
|
Zoetis Q3: Strong Osteoarthritis Pain Franchise
- I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and SOLENSIA, delivered 97% operational revenue growth, with LIBRELA poised to become a $1 billion franchise. Zoetis projects 10–11% operational revenue growth and 13.5–14.5% adjusted net income growth for FY24, despite minor headwinds from China.
- 11/10/2024
|
Zoetis to Participate in Jefferies London Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available.
- 11/07/2024
|
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
- ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
- 11/04/2024
|
Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript
- Zoetis Inc. (NYSE:ZTS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Brandon Vazquez - William Blair Jon Block - Stifel David Westenberg - Piper Sandler Balaji Prasad - Barclays Glen Santangelo - Jefferies Chris Schott - JPMorgan Chris LoBianco - TD Cowen Navann Ty - BNP Paribas Operator Welcome to the Third Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
- 11/04/2024
|
Zoetis raises full-year guidance on strong Q3 results
- Zoetis Inc (NYSE:ZTS, ETR:ZOE) delivered another impressive quarter, with revenue and earnings exceeding Wall Street estimates for the third quarter of fiscal year 2024. For the period ended September 30, 2024, the animal health company reported revenues of $2.39 billion, marking an 11% increase year-over-year from $2.15 billion in Q3 2023, and surpassing analyst expectations of $2.29 billion.
- 11/04/2024
|
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Fraud
- LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 11/04/2024
|
Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/04/2024
|
Zoetis raises annual forecasts on strong demand for pet treatments
- Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.
- 11/04/2024
|
Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
- Zoetis (ZTS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.36 per share a year ago.
- 11/04/2024
|
Zoetis Announces Third Quarter 2024 Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue and adjusted EPS. The company reported revenue of $2.4 billion for the third quarter of 2024, an increase of 11% compared with the third quarter of 2023. On an operational1 basis, revenue for the third quarter of 2024 increased 14% compared with the third quarter of 2023. Net income for the third quarter of 2024 was $682.
- 11/04/2024
|
My Top 15 High-Growth Dividend Stocks For November 2024
- The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.
- 11/03/2024
|
Zoetis Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 11/03/2024
|
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 11/02/2024
|
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
- 11/01/2024
|
Gear Up for Zoetis (ZTS) Q3 Earnings: Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
- 10/30/2024
|
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
- ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
- 10/29/2024
|
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
- Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2024
|
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/27/2024
|
Zoetis Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
- LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/26/2024
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- 10/25/2024
|
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
- Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/21/2024
|
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/21/2024
|
Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
- LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/20/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/19/2024
|
Zoetis Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/18/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/17/2024
|
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 10/16/2024
|
Pet DNA Testing Market Report 2024: Industry Analysis and Forecast (2018-2030) with Share & Strategy Insights of Leading Players - Zoetis (Basepaws), Mars Petcare (Wisdom Panel), Orivet Genetic Pet Care & More
- Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Pet DNA Testing Market Size, Share and Trends Analysis 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global pet DNA testing market is expected to reach USD 676.64 million by 2030, registering to grow at a CAGR of 9.45% from 2024 to 2030.
- 10/15/2024
|
Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/14/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/13/2024
|
Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/12/2024
|
Investors Are Encouraged To Help The Schall Law Firm Look Into Whether Zoetis Inc. Violated Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/11/2024
|
Zoetis Declares Fourth Quarter 2024 Dividend
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Afte.
- 10/10/2024
|
The Schall Law Firm Urges Shareholder Participation In An Investigation Into Zoetis Inc For Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/10/2024
|
Zoetis Inc. Is Being Inquired Into For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/09/2024
|
Zoetis: A Solid Choice For The Young Dividend Growth Investor
- Zoetis excels in innovation, creating new categories and consistently raising the standard of care, outperforming competitors with strong execution. Disciplined capital allocation is evident with strategic exits and reinvestments in high-return growth areas, ensuring sustained business growth. Their market leadership, potential growth opportunities, and dividend metrics make ZTS a suitable candidate for the young dividend growth investor.
- 10/09/2024
|
The Schall Law Firm Urges Shareholder Participation In An Investigation Into Zoetis Inc For Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/08/2024
|
Zoetis Inc. Is Being Looked Into For Securities Law Violations And Investors Are Encouraged To Reach Out To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/07/2024
|
The Schall Law Firm Urges Shareholders To Help Investigate Whether Zoetis Inc Committed Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/06/2024
|
Investors Are Invited To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Related Infractions
- LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/05/2024
|
Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Encourages Impacted Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/04/2024
|
My Top 15 High Growth Dividend Stocks For October 2024
- The SPDR S&P 500 ETF Trust posted a gain of 2.10% in September as it continues marching on in 2024. The Top 15 dividend growth stocks for October 2024 offer an average dividend yield of 1.05% and appear to be about 20% undervalued based on dividend yield theory.
- 10/03/2024
|
Investors Are Urged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Related Infractions
- LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/03/2024
|
Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Encourages Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/02/2024
|
Investors Are Invited To Help The Schall Law Firm Look Into Whether Zoetis Inc. Violated Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/01/2024
|
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 09/30/2024
|
The Schall Law Firm Wants Shareholders To Contribute To A Securities Fraud Investigation Into Zoetis Inc
- LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/30/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Violating Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/29/2024
|
Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders With Losses To Lend A Hand
- LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/28/2024
|
The Schall Law Firm Is Looking Into Whether Zoetis Inc. Violated Securities Laws And Affected Investors Should Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/27/2024
|
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
- Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.
- 09/27/2024
|
Zoetis: Investing In Pet Health And Portfolio Wealth
- Zoetis, a leader in veterinary healthcare, has consistently outperformed the market with robust revenue growth and strong margins, even during industry challenges. The company's innovation, focus on companion animals, and strategic divestitures position it well for continued growth, despite prior concerns over drug risks. With a modest dividend yield, Zoetis remains a solid investment for dividend growth, backed by a $6 billion buyback program and long-term market potential.
- 09/26/2024
|
Shareholders Are Urged To Join The Schall Law Firm's Inquiry Into Zoetis Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/26/2024
|
Zoetis and Danone Announce Strategic Partnership to Pioneer Sustainable Innovation in Dairy Farming Using the Power of Genetics
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today's dairy farms through the power of genetics for healthier cows. Combining Danone's commitment to environmental stewardship with Zoetis' expertise in animal genetics, the partnership aims to innovate the dairy industry's approach to breeding for sustainability. The plan between the two companies is intended to enable Danone to leverage Zoetis' cutting-.
- 09/26/2024
|
Zoetis Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/25/2024
|
3 Top Dividend Stocks Poised To Outshine In A Fed-Cutting Frenzy
- Optimism is growing as inflation eases and rate cuts drive the market. However, uncertainties remain, making selective, high-quality stock picks crucial. Despite high valuations, focusing on dividend stocks with strong fundamentals offers long-term growth and income potential in this evolving environment. I highlight three stocks that balance income, growth, and value, each positioned to outperform in a market fueled by economic shifts and favorable conditions.
- 09/25/2024
|
The Schall Law Firm Has Launched An Inquiry Into Zoetis Inc For Securities Fraud And Shareholders Are Urged To Join
- LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/24/2024
|
Zoetis Inc. Is Being Looked Into For Possible Securities Law Violations And The Schall Law Firm Invites Impacted Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/23/2024
|
Shareholders Are Encouraged To Help The Schall Law Firm Investigate Whether Zoetis Inc Engaged In Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/22/2024
|
Zoetis Inc. Is Being Looked Into For Violating Securities Laws And The Schall Law Firm Urges Investors To Join The Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/21/2024
|
The Schall Law Firm Is Investigating Zoetis Inc For Possible Securities Fraud And Shareholders With Losses Should Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/20/2024
|
Zoetis Inc. May Have Violated Securities Regulations And Investors Are Invited To Join The Schall Law Firm's Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/19/2024
|
Zoetis to Host Webcast and Conference Call on Third Quarter 2024 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentat.
- 09/19/2024
|
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
- ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
- 09/18/2024
|
The Schall Law Firm Is Looking Into Zoetis Inc For Possible Securities Fraud And Affected Stockholders Are Urged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/18/2024
|
Investors Can Help The Schall Law Firm Investigate Zoetis Inc. For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/17/2024
|
Zoetis Inc May Have Defrauded Shareholders And The Schall Law Firm Encourages Those With Losses To Participate In An Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/16/2024
|
The Schall Law Firm Is Looking Into Zoetis Inc. For Possible Securities Fraud And Impacted Investors Are Invited To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/15/2024
|
Zoetis Inc May Have Violated Securities Laws And The Schall Law Firm Urges Public Participation In An Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/14/2024
|
Zoetis (ZTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- In the most recent trading session, Zoetis (ZTS) closed at $191.09, indicating a +0.2% shift from the previous trading day.
- 09/13/2024
|
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
- 09/13/2024
|
Shareholders Are Invited To Partake In The Schall Law Firm's Investigation Into Zoetis Inc.'s Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/13/2024
|
The Schall Law Firm Is Looking Into Whether Zoetis Inc Committed Securities Related Infractions And The Firm Seeks Investor Participation
- LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/12/2024
|
Zoetis Inc. Is Being Investigated For Possible Securities Law Violations And Affected Stockholders Are Encouraged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/11/2024
|
The Schall Law Firm Is Looking Into Whether Zoetis Inc Committed Securities Fraud And Investors Can Partake In The Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/10/2024
|
Zoetis Inc. Is Being Investigated For Possibly Violating Securities Regulations And The Schall Law Firm Encourages Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/09/2024
|
The Schall Law Firm Is Looking Into Whether Zoetis Inc Committed Securities Fraud And Investors Are Urged To Partake In An Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/07/2024
|
Shareholders Who Have Losses In Zoetis Inc. Are Invited To Join The Schall Law Firm's Inquiry Into Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/06/2024
|
Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
- Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
- 09/05/2024
|
Zoetis Inc Is Being Looked Into For Possibly Defrauding Shareholders And The Schall Law Firm Seeks The Public's Assistance
- LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/05/2024
|
Zoetis Inc (ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
- Zoetis Inc (NYSE:ZTS ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 1:05 PM ET Company Participants Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Thanks, and good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference.
- 09/04/2024
|
The Schall Law Firm Is Investigating Whether Zoetis Inc. Violated Securities Laws And Investors Can Lend A Hand
- LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/04/2024
|
Shareholders Are Encouraged To Partake In The Schall Law Firm's Inquiry Into Zoetis Inc For Potential Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/03/2024
|
My Top 15 High Growth Dividend Stocks For September 2024
- The SPDR S&P 500 ETF Trust posted a 2.34% gain in August, underperforming Vanguard's Dividend Appreciation Index Fund ETF Shares by +3.32%. The top 15 dividend growth stocks for September 2024 offer an average dividend yield of 1.23% and appear to be about 26% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved a 12.93% annualized return.
- 09/03/2024
|
Zoetis Inc. Is Being Looked Into By The Schall Law Firm For Securities Law Infractions And Impacted Investors Should Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/02/2024
|
The Schall Law Firm Urges Individuals With Losses In Zoetis Inc To Join A Securities Fraud Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/01/2024
|
Zoetis Inc. Might Have Violated Securities Laws And Stockholders Are Encouraged To Contact The Schall Law Firm About An Investigation
- LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/31/2024
|
The Schall Law Firm Invites Investors In Zoetis Inc To Assist In An Inquiry Into Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/30/2024
|
Zoetis Inc. May Have Committed Securities Law Violations And Shareholders Are Urged To Help The Schall Law Firm Investigate
- LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/29/2024
|
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 08/28/2024
|
An Inquiry Has Been Launched Into Zoetis Inc's Possible Securities Fraud And The Schall Law Firm Invites The Public's Assistance
- LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/28/2024
|
Zoetis Inc May Have Violated Securities Regulations And The Schall Law Firm Wants Help With The Investigation
- LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/27/2024
|
A Securities Fraud Inquiry Into Zoetis Inc Has Been Launched And The Schall Law Firm Is Asking Shareholders To Participate
- LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/26/2024
|
The Schall Law Firm Is Urging Investors In Zoetis Inc. To Join An Investigation Into Possible Securities Law Infractions
- LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/25/2024
|
An Inquiry Into Zoetis Inc. For Securities Fraud Has Been Opened By The Schall Law Firm And Stockholders Are Invited To Take Part
- LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/24/2024
|
The Schall Law Firm Is Investigating Zoetis Inc For Possible Violations Of Securities Laws And Investors Are Encouraged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/23/2024
|
Shareholders With Losses In Zoetis Inc Are Invited By The Schall Law Firm To Participate In A Securities Fraud Inquiry
- LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/22/2024
|
The Schall Law Firm Is Investigating Zoetis Inc For Possible Securities Law Violations And Invites Shareholders To Participate
- LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/20/2024
|
The Schall Law Firm Is Investigating Securities Violations By Zoetis Inc And Invites Investors To Join
- LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/16/2024
|
The Schall Law Firm Is Looking Into Securities Violations By Zoetis Inc And Urges Investors To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/15/2024
|
The Highest Quality Dividend-Growth Healthcare Stocks
- Quality Snapshots evaluate dividend-growth companies based on five quality factors including financial performance, resilience and dividend safety. This healthcare sector overview identifies 26 top quality stocks in the sector. Johnson & Johnson and Zoetis discussed as high-quality, fairly valued healthcare stocks with very different yields and growth rates.
- 08/15/2024
|
The Schall Law Firm Is Investigating Zoetis Inc And Urges Investors With Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/14/2024
|
The Schall Law Firm Is Probing Zoetis Inc And Encourages Investors With Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/13/2024
|
Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
- Conservative estimates suggest Librela could easily reach management's $1 billion sales target without considering international markets or Solensia (its feline counterpart), which are included in management's target calculation. Current sales data and management commentary show rapid adoption and high customer satisfaction, with Librela alone already generating a $460 million annualized revenue run rate just one year after its U.S. launch. Librela's outperformance is likely to be a significant tailwind for Zoetis' stock price, given the market's sensitivity to news about the drug's performance.
- 08/13/2024
|
Which Pet Stock Should Get Your Tail Wagging in 2024?
- It's not a sector as red-hot as artificial intelligence, but pet stocks warrant investor attention in 2024. According to PetExec, U.S. households spend over $136 billion per year on their pets.
- 08/13/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors Who Have Incurred Losses Are Urged To Reach Out
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/12/2024
|
Top 3 stocks to consider amidst a slowing US economy
- As the US economy shows signs of slowing, highlighted by recent jobs data falling short of expectations, investors are seeking stable opportunities. According to David Kostin, Chief US Equity Strategist at Goldman Sachs, shifting focus to resilient stocks could be crucial.
- 08/11/2024
|
Zoetis Inc Is Under The Schall Law Firm's Investigation And Investors With Losses Are Urged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/09/2024
|
Zoetis Inc Is Being Investigated By The Schall Law Firm And Investors With Losses Are Encouraged To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/08/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors Who Have Incurred Losses Are Urged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/07/2024
|
Zoetis (ZTS) Just Flashed Golden Cross Signal: Do You Buy?
- After reaching an important support level, Zoetis (ZTS) could be a good stock pick from a technical perspective. ZTS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
- 08/07/2024
|
Zoetis (ZTS) Just Reclaimed the 200-Day Moving Average
- From a technical perspective, Zoetis (ZTS) is looking like an interesting pick, as it just reached a key level of support. ZTS recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
- 08/07/2024
|
Zoetis (ZTS) Just Overtook the 50-Day Moving Average
- Zoetis (ZTS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ZTS broke out above the 50-day moving average, suggesting a short-term bullish trend.
- 08/07/2024
|
Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
- Zoetis stock price increased by 8.6% since last publication, underperforming S&P 500 index. Company raised full-year guidance, expecting double-digit growth, driven by DTC strategy and new products. Upgraded rating to 'Buy' with $210 target price per share, expecting revenue growth and margin expansion.
- 08/07/2024
|
Zoetis Inc Is Being Investigated By The Schall Law Firm And Investors With Losses Are Encouraged To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/06/2024
|
Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say
- The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/06/2024
|
Zoetis Raises Guidance on Revenue Growth
- Zoetis (ZTS) stock surged in intraday trading Tuesday after the company beat second-quarter revenue expectations and raised its full-year guidance.
- 08/06/2024
|
Animal Health Firm Zoetis Clocks Strong Q2 Earnings, Companion Animal Operations Boost Confidence For 2024
- On Tuesday, Zoetis Inc ZTS stock is trading higher after the company reported better-than-expected second-quarter financial results and raised its 2024 guidance above estimates.
- 08/06/2024
|
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
- Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
- 08/06/2024
|
Why Zoetis Stock Was Moving Higher Tuesday
- Zoetis beat estimates on the top and bottom lines. Both the companion animal and livestock segments delivered solid growth.
- 08/06/2024
|
Zoetis Lifts Revenue, Profit Outlook
- Adjusted earnings per share topped analyst estimates. Net income fell 7% year over year to $624 million.
- 08/06/2024
|
Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates
- Zoetis (ZTS) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.41 per share a year ago.
- 08/06/2024
|
Zoetis lifts 2024 results forecasts on strong demand for pet treatments
- Animal healthcare company Zoetis raised its annual profit and revenue forecasts on Tuesday, betting on strong demand for its medicines and vaccines for pets.
- 08/06/2024
|
UTHR or ZTS: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 08/02/2024
|
My Top 15 High-Growth Dividend Stocks For August 2024
- The SPDR S&P 500 ETF Trust posted a 1.21% gain in July, underperforming Vanguard's Dividend Appreciation Index Fund ETF Shares by +3.97%. The top 15 dividend growth stocks for August 2024 offer an average dividend yield of 1.49% and appear to be about 28% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved a 12.25% annualized return.
- 08/02/2024
|
Zoetis (ZTS) Advances While Market Declines: Some Information for Investors
- In the most recent trading session, Zoetis (ZTS) closed at $182.42, indicating a +1.32% shift from the previous trading day.
- 08/01/2024
|
Zoetis Announces Authorization of Multi-Year $6 Billion Share Repurchase Program
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that its Board of Directors has approved a multi-year $6 billion share repurchase program as part of its capital allocation plans. The demand for Zoetis' innovative and market-leading portfolio has enabled the company to execute its disciplined capital allocation strategy by reinvesting in growth opportunities and returning capital to shareholders, while delivering long-term value. “Our consistently strong performance in.
- 08/01/2024
|
Unveiling Zoetis (ZTS) Q2 Outlook: Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
- 08/01/2024
|
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
- Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2024
|
Zoetis Inc Is Being Investigated By The Schall Law Firm And Investors With Losses Are Encouraged To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/30/2024
|
Zoetis Inc Is Being Investigated By The Schall Law Firm And Investors With Losses Are Encouraged To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/29/2024
|
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
- Zoetis (ZTS) reachead $179.84 at the closing of the latest trading day, reflecting a -0.51% change compared to its last close.
- 07/26/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors With Losses Are Urged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/26/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors With Losses Are Urged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/25/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors With Losses Are Urged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/24/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors With Losses Are Urged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/23/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors With Losses Are Urged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
Investors With Losses Are Encouraged By The Schall Law Firm To Reach Out Amidst Zoetis Incorporated Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/19/2024
|
Zoetis Incorporated Is Being Probed By The Schall Law Firm And Investors With Losses Are Urged To Connect
- LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/18/2024
|
The Schall Law Firm Is Probing Zoetis Inc And Invites Investors Who Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/17/2024
|
Zoetis Inc Is Under Investigation By The Schall Law Firm And Investors With Losses Are Called To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/16/2024
|
The Schall Law Firm Begins A Probe Into Allegations Against Zoetis Inc And Invites Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/15/2024
|
Investors Of Zoetis Inc With Losses Are Encouraged To Contact As The Schall Law Firm Initiates A Probe Into Claims
- LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/13/2024
|
Zoetis Inc Investors With Losses Are Urged To Reach Out As The Schall Law Firm Begins An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/12/2024
|
The Top 3 Long-Term Stocks to Buy for Decades of Gains
- One key principle of long-term investing is letting your winners run. Charlies Munger reiterated this idea in his famous maxim; “The first rule of compounding: Never interrupt it unnecessarily.
- 07/12/2024
|
Investors With Losses Are Encouraged To Contact As The Schall Law Firm Initiates An Investigation Into Claims Against Zoetis Inc
- LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/11/2024
|
Australia Veterinary Pharmaceutical Manufacturing Industry Market Research Report 2024 Featuring Virbac, Zoetis, and Intervet Schering-Plough Animal Health
- Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering. This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
- 07/11/2024
|
The Schall Law Firm Begins A Probe Into Allegations Against Zoetis Inc And Urges Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/10/2024
|
Investigation Into Claims Against Zoetis Inc Is Initiated By The Schall Law Firm And Investors Who Have Suffered Losses Are Encouraged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/09/2024
|
3 Pet Stocks That Are Better Buys Than Chewy
- Chewy (NYSE: CHWY ) has recently become what some would consider to be a meme stock. On June 24, influential investor Keith Gill, also known as Roaring Kitty, disclosed the purchase of 9 million shares, valued at roughly $245 million.
- 07/08/2024
|
USNA vs. ZTS: Which Stock Is the Better Value Option?
- Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/08/2024
|
The Schall Law Firm Begins Investigation Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/08/2024
|
Zoetis Deep Dive: Better Setup Than Human Pharma
- Zoetis is a leading animal pharmaceutical developer with 92% of sales from animal pharmaceuticals, over two-thirds of which are for pets. The company's competitive advantage lies in its R&D success, lower spending on R&D compared to human pharma, and a distribution network of unrivaled scale. Zoetis' growth is driven by pet humanization trends, but future success hinges on innovation and new drug releases, particularly the upcoming drug Librela.
- 07/08/2024
|
The Schall Law Firm Commences Inquiry Into Claims Against Zoetis Inc And Invites Investors With Losses To Communicate
- LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/07/2024
|
My Top 15 High-Growth Dividend Stocks For July 2024
- The SPDR S&P 500 ETF Trust had a 3.53% gain in June, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares, +1.41%. The top 15 dividend growth stocks for July 2024 offer an average dividend yield of 1.56% and appear to be about 31% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved an 11.07% annualized return.
- 07/07/2024
|
The Schall Law Firm Initiates Examination Of Accusations Against Zoetis Inc And Urges Investors With Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/06/2024
|
The Schall Law Firm Starts Probe Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/05/2024
|
Zoetis: Still A High Quality Business Led By Companion Animal Growth
- Zoetis's stock has slumped in 2024, partly due to recent safety concerns regarding the company's arthritis drugs. Despite these safety concerns, Zoetis grew total revenue by 10% compared to Q1 2023 and raised their full-year 2024 revenue guidance. The company's companion animal products are supporting Zoetis's growth as the company sees a large opportunity with their osteoarthritis pain drugs.
- 07/04/2024
|
Investors With Losses Are Invited By The Schall Law Firm To Reach Out As They Start Investigation Into Claims Against Zoetis Inc
- LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/03/2024
|
Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
- Zoetis is a resilient company that shows strong growth even in times of economic challenges. The company is well-positioned in a growing market and has a strong product portfolio, including a new potential billion-franchise in osteoarthritis pain. ZTS has shown impressive dividend growth in recent years, and it is likely this will continue in the future, making it attractive for dividend investors with a long time horizon.
- 07/03/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Zoetis Inc And Invites Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/02/2024
|
The Schall Law Firm Starts Probe Into Accusations Against Zoetis Inc And Encourages Investors With Losses To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/01/2024
|
Forget The S&P 500 - 3 Fantastic Dividend Stocks With Double-Digit Return Potential
- The S&P 500's first-half surge, driven by AI giants, poses diversification risks. Its concentration may lead to underperformance if the AI rally slows down. This tech-heavy market has left many great stocks undervalued. Identifying these opportunities is key to navigating potential future market shifts effectively. I've found three dividend stocks with strong potential and attractive valuations, offering a strategic way to diversify and capitalize on market imbalances.
- 07/01/2024
|
The Schall Law Firm Commences Investigation Into Allegations Against Zoetis Inc And Calls For Investors With Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/30/2024
|
The Schall Law Firm Begins Inquiry Into Claims Against Zoetis Inc And Invites Investors With Losses To Connect
- LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/29/2024
|
Zoetis CEO Kristin Peck sits down with Jim Cramer
- Zoetis CEO Kristin Peck joins 'Mad Money' host Jim Cramer to talk the state of pet health care, research and development investments, Avian Flu treatments and more.
- 06/28/2024
|
The Schall Law Firm Launches Probe Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/28/2024
|
The Schall Law Firm Initiates Examination Into Allegations Against Zoetis Inc And Urges Investors With Losses To Communicate
- LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/27/2024
|
The Schall Law Firm Initiates Investigation Into Claims Against Zoetis Inc And Urges Affected Investors To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/26/2024
|
7 Biotech Stocks to Boost Your Portfolio to Peak Health
- While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.
- 06/26/2024
|
Zoetis Foundation and Zoetis Deepen Commitment to Global Disaster Relief with American Red Cross and American Humane
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DriventoCare--As animals and communities continue to face mounting challenges from natural disasters, Zoetis Inc. and the Zoetis Foundation are committed to supporting animal health and community resilience. The Zoetis Foundation brings this commitment to life through grant support to the American Red Cross, which will help provide necessary emergency preparedness and relief to families and communities impacted by disasters. Zoetis Inc. partners with American Humane to incr.
- 06/26/2024
|
The Schall Law Firm Launches Probe Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/25/2024
|
The Schall Law Firm Initiates Investigation Into Claims Against Zoetis Inc And Urges Investors With Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/24/2024
|
The Schall Law Firm Commences Probe Into Allegations Against Zoetis Inc (NYSE:ZTS) And Encourages Investors Experiencing Losses To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2024
|
The Schall Law Firm Starts Investigation Into Claims Against Zoetis Inc (NYSE:ZTS) And Motivates Investors Suffering Losses To Initiate Contact
- LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/22/2024
|
The Schall Law Firm Begins Inquiry Into Allegations Against Zoetis Inc (NYSE:ZTS) And Encourages Investors With Losses To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/21/2024
|
USNA or ZTS: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 06/21/2024
|
The Schall Law Firm Initiates Investigation Into Claims Against Zoetis Inc (NYSE:ZTS) And Urges Investors With Losses To Contact Them
- LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/20/2024
|
The Schall Law Firm Has Started A Probe Into Allegations Against Zoetis Inc (NYSE:ZTS) And Encourages Investors Who Have Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/19/2024
|
The Schall Law Firm Begins Probe Into Allegations Against Zoetis Inc And Encourages Affected Investors To Connect
- LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/18/2024
|
The Schall Law Firm Has Initiated An Investigation Into Claims Against Zoetis Inc (NYSE:ZTS) And Urges Investors Who Have Suffered Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/17/2024
|
The Schall Law Firm Has Begun A Probe Into Allegations Against Zoetis Inc. (NYSE:ZTS) And Encourages Investors Who Have Incurred Losses To Reach Out
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/11/2024
|
Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader
- Zoetis is a leading animal healthcare company. In April, ZTS stock suffered a steep plunge due to negative media publicity over Librela and Solensia. Zoetis still expects Librela and Solensia to achieve peak sales of $1 billion globally.
- 06/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE:ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/09/2024
|
The Schall Law Firm Has Begun A Probe Into Allegations Against Zoetis Inc. (NYSE:ZTS) And Encourages Investors Who Have Experienced Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/09/2024
|
The Schall Law Firm Has Initiated An Investigation Into Accusations Against Zoetis Inc. (NYSE:ZTS) And Urges Investors Who Have Suffered Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/08/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/07/2024
|
The Schall Law Firm Announces An Inquiry Into Allegations Against Zoetis Inc. (NYSE:ZTS) And Encourages Investors Who Have Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/07/2024
|
The Schall Law Firm Declares An Investigation Into Claims Against Zoetis Inc. (NYSE:ZTS) And Urges Investors Who Have Suffered Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/06/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/05/2024
|
The Schall Law Firm Announces A Probe Into Allegations Against Zoetis Inc. (NYSE:ZTS) And Encourages Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/05/2024
|
USNA vs. ZTS: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 06/05/2024
|
Zoetis Releases 2023 Sustainability Report to Share Progress in Building a Better Future for Communities, Animals and the Planet
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis Inc. today published its 2023 Sustainability Report “Advancing Sustainability in Animal Health for a Better Future,” to highlight the company's progress in achieving its Driven to Care long-term sustainability aspirations and provide continued disclosure on environmental, social and governance (ESG) topics. The report shares Zoetis' actions to meet aspirations across three pillars: Communities, Animals and Planet. Included in the report is the company's.
- 06/05/2024
|
The 7 Best Dividend Stocks to Buy in June 2024
- You may have heard the pithy investing mantra to “sell in May and go away.” Because stocks tend to underperform during the summer months, the idea is to sit them out and wait for better opportunities in the fall.
- 06/05/2024
|
The Schall Law Firm Declares an Examination into Accusations Against Zoetis Inc. and Urges Investors with Losses to Communicate
- LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/04/2024
|
ZTS INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/03/2024
|
My Top 15 High Growth Dividend Stocks For June 2024
- The SPDR S&P 500 ETF Trust had a 5.06% gain in May, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares, +3.33%. The top 15 dividend growth stocks for June 2024 offer an average dividend yield of 1.37% and appear to be about 28% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved an 11.12% annualized return, beating VIG by 0.10% but trailing SPY by 2.18%.
- 06/03/2024
|
IMPORTANT INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/02/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE:ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/01/2024
|
IMPORTANT INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/01/2024
|
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/31/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/30/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/30/2024
|
Beat the Dow Jones With This Cash-Gushing Dividend Stock
- Zoetis is the clear leader in the global animal healthcare industry. Its newest osteoarthritis medications are seeing early success.
- 05/30/2024
|
Zoetis CEO Kristin Peck sits down with Jim Cramer
- Zoetis CEO Kristin Peck joins 'Mad Money' host Jim Cramer to talk the animal health space, its pharmaceutical offerings, pet wellness trends and more.
- 05/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/23/2024
|
Zoetis Declares Third Quarter 2024 Dividend
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the third quarter of 2024. The dividend will be paid on Wednesday, September 4, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, July 18, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After.
- 05/22/2024
|
Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
- Zoetis stock has underperformed the market since my previous article, but long-term investors should double down today due to the strengthening companion animal business. The companion animal segment is growing rapidly, driven by factors such as the humanization of pets and increasing awareness of pet healthcare. Zoetis is well-positioned to benefit from the growth of the companion animal market, particularly in Latin America.
- 05/22/2024
|
Zoetis to Participate in the William Blair 44th Annual Growth Stock Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:40 p.m. CT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentatio.
- 05/21/2024
|
Zoetis Inc. (NYSE:ZTS) Shares Purchased by Meridian Wealth Management LLC
- Meridian Wealth Management LLC grew its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 18.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,541 shares of the company’s stock after buying an additional 239 shares during the quarter. Meridian Wealth Management LLC’s holdings in Zoetis were worth $304,000 at the end of the most recent quarter. Other institutional investors and hedge funds have also made changes to their positions in the company. Vaughan Nelson Investment Management L.P. acquired a new position in shares of Zoetis in the third quarter valued at approximately $176,219,000. Alphinity Investment Management Pty Ltd increased its stake in shares of Zoetis by 214.7% during the 4th quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock valued at $162,662,000 after acquiring an additional 562,259 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Zoetis by 27,671.0% in the fourth quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock worth $94,605,000 after acquiring an additional 477,602 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Zoetis by 34.8% during the third quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock worth $271,764,000 after purchasing an additional 403,164 shares during the period. Finally, Natixis Advisors L.P. boosted its holdings in shares of Zoetis by 53.9% in the 3rd quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock valued at $163,753,000 after purchasing an additional 329,543 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors. Zoetis Trading Up 0.2 % Shares of ZTS stock opened at $174.06 on Monday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market capitalization of $79.42 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.70 and a beta of 0.86. The stock has a fifty day moving average of $164.65 and a two-hundred day moving average of $179.52. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. Zoetis’s revenue was up 9.5% compared to the same quarter last year. As a group, research analysts expect that Zoetis Inc. will post 5.77 EPS for the current year. Insider Buying and Selling In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares in the company, valued at $2,725,267.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders. Wall Street Analysts Forecast Growth A number of equities research analysts have issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. HSBC reduced their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Stifel Nicolaus reduced their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group lowered their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $211.75. Read Our Latest Stock Analysis on Zoetis About Zoetis (Free Report) Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
- 05/20/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/19/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/18/2024
|
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/17/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/16/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/16/2024
|
Zoetis to Participate in the Stifel 2024 Jaws and Paws Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:05 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will al.
- 05/16/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/15/2024
|
Zoetis Named a Top Company for DE&I by Fair360 (Formerly DiversityInc.)
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DEI--Zoetis Inc. (NYSE:ZTS) has been named to Fair360's Top 50 Companies list for the first time, underscoring the company's progress and sustained commitment to advancing Diversity, Equity and Inclusion (DE&I). Zoetis is the only animal health company included in this year's Top 50 rankings. “Zoetis' DE&I focus begins with our dedicated Board of Directors and executive team of diverse experiences, backgrounds, and perspectives, promoting an inclusive envir.
- 05/14/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
- NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/06/2024
|
Is Trending Stock Zoetis Inc. (ZTS) a Buy Now?
- Zacks.com users have recently been watching Zoetis (ZTS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 05/06/2024
|
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS
- NEW YORK , May 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zoetis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/03/2024
|
Zoetis: Long-Term Buy Despite Safety Concerns
- Zoetis is a leader in animal health, focusing on R&D to develop innovative medicines and technologies for pets and livestock. Concerns have arisen about the safety of their drugs, but Zoetis appears confident and reported impressive revenue growth. The stock experienced volatility but has since recovered, and the long-term outlook for Zoetis remains positive.
- 05/03/2024
|
My Top 15 High Growth Dividend Stocks For May 2024
- The SPDR S&P 500 ETF Trust had a 4.03% loss in April, slightly outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares, -4.13%.
- 05/03/2024
|
Why Zoetis Stock Popped by Almost 6% on Thursday
- The animal health products purveyor unveiled its first-quarter results. It posted encouraging growth on both the top and bottom lines.
- 05/02/2024
|
Zoetis CFO On The Pet Care Industry
- Zoetis CFO breaks down the pet advanced care industry.
- 05/02/2024
|
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
- Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
- 05/02/2024
|
Zoetis Inc (ZTS) Q1 2024 Earnings Call Transcript
- Zoetis Inc (NYSE:ZTS ) Q1 2024 Results Conference Call May 2, 2024 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley David Westenberg - Piper Sandler Brandon Vazquez - William Blair Christopher LoBianco - TD Cowen Nathan Rich - Goldman Sachs Balaji Prasad - Barclays Glen Santangelo - Jefferies Chris Schott - JPMorgan Navann Ty - BNP Operator Welcome to the First Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
- 05/02/2024
|
Zoetis CEO Kristin Peck on Q1 earnings
- Zoetis CEO Kristin Peck joins 'Money Movers' to discuss the company's quarterly earnings results, what the growth is attributable to, and what differentiates Zoetis from competitors.
- 05/02/2024
|
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
- The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 05/02/2024
|
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
- Zoetis (ZTS) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.34 per share. This compares to earnings of $1.31 per share a year ago.
- 05/02/2024
|
Zoetis beats profit estimates on strong demand for pet products
- Animal healthcare company Zoetis surpassed analysts' expectations for first-quarter profit on Thursday, helped by strong demand for its medicines and vaccines for pets.
- 05/02/2024
|
Zoetis Announces First Quarter 2024 Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024. The company reported revenue of $2.2 billion for the first quarter of 2024, an increase of 10% compared with the first quarter of 2023. On an operational1 basis, revenue for the first quarter of 2024 increased 12% compared with the first quarter of 2023. Net income for the first quarter of 2024 was $599 million, or $1.31 per di.
- 05/02/2024
|
Zoetis Reports Earnings Thursday. The Company Must Address Dog Pain Drug Safety Worries.
- The animal health firm has had a tough year with shares down nearly 20% amid negative media reports about a key new medicine.
- 05/01/2024
|
Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI
- Fortune.com recently reported that artificial intelligence (AI) is helping the pet care industry cope with a chronic veterinary shortage. AI use cases could become far more prevalent for pets than humans in the near term due to fewer impediments such as privacy laws.
- 05/01/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/30/2024
|
1 Magnificent Dividend Growth Stock That's Down 40% and Trading at a Once-in-a-Decade Valuation
- Zoetis is the leader in the global animal healthcare industry. However, it has run into a trio of short-term issues.
- 04/30/2024
|
Unveiling Zoetis (ZTS) Q1 Outlook: Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
- 04/29/2024
|
Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 04/26/2024
|
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
- In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.
- 04/22/2024
|
Suddenly, There's An Alternative - The Important Case For Wide Moat Dividend Stocks
- Short-term bonds currently yield more than stocks, indicating a shift in the investment environment. Investors should focus on companies with healthy balance sheets, pricing power, and that are trading below their fair value. We suggest several favorite wide-moat dividend businesses.
- 04/18/2024
|
Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
- Zoetis Inc. has seen a significant decline in its stock price, dropping more than 24% since January. The decline is partly due to market weakness and the ongoing growth to value rotation, as well as headlines about the potential adverse effects of one of its key drugs. Despite the setbacks, Zoetis' core business remains strong, with robust top-line and bottom-line growth expectations, diversified growth opportunities, and a stable dividend.
- 04/14/2024
|
Zoetis shares drop amid concerns over arthritis shots' safety for pets
- Zoetis Inc (NYSE:ZTS, ETR:ZOE) shares took a hit Friday after a Wall Street Journal report that suggested the company's arthritis shots may have sickened dogs and cats. The arthritis shots, Librela and Solensia, target osteoarthritis by focusing on nerve growth factor protein.
- 04/12/2024
|
Zoetis Stock Falls on Concerns Over Pet Arthritis Drugs. Company Says They're Safe.
- An article in The Wall Street Journal highlights the scrutiny over the company's arthritis treatments for pets.
- 04/12/2024
|
Zoetis's stock falls 7% to lead S&P 500 decliners after report its arthritis shots have sickened pets
- Zoetis Inc.'s stock ZTS, -7.77% tumbled 7% Friday to lead S&P 500 decliners, after a Wall Street Journal report that the company's arthritis shots Librela and Solensia may have sickened pet cats and dogs. The two shots won Food and Drug Administration approval in 2022 and 2023 as the first antibody drugs for pets.
- 04/12/2024
|
Why Zoetis (ZTS) Dipped More Than Broader Market Today
- The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.
- 04/08/2024
|
My Top 15 High Growth Dividend Stocks For April 2024
- The SPDR S&P 500 ETF Trust had a 3.27% return in March, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares. The top 15 dividend growth stocks for April 2024 offer an average dividend yield of 1.44% and appear to be about 24% undervalued based on dividend yield theory.
- 04/01/2024
|
Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks of March?
- Lululemon offered weaker-than-expected guidance in its fourth-quarter earnings report. Southwest cut its guidance in response to the crisis at Boeing.
- 04/01/2024
|
Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentation.
- 03/28/2024
|
You Don't Have To Take Excess Risk To Beat The Market
- It is possible for retail investors to consistently beat the market by owning above-average blue chip dividend growth stocks. Hard work, research, and staying rational are key factors in outperforming the market. I highlight specific blue chip stocks, such as Booking Holdings, Zoetis, UnitedHealth Group, and Elevance Health, that have strong growth potential and attractive valuations.
- 03/25/2024
|
Zoetis: My Favorite Healthcare Stock Right Now
- Zoetis Inc. has shown unique compounding results since spinning off from Pfizer, with double-digit EPS and dividend growth CAGRs since inception. The loneliness epidemic is driving demand for companion animals, and Zoetis is well positioned to benefit from the rise in pet ownership and pet-related spending. Zoetis has a strong position in the animal health market, with increased pricing power and limited competition, making it a best-in-class asset in the industry.
- 03/21/2024
|
My Top 15 High Growth Dividend Stocks For March 2024
- The SPDR S&P 500 ETF Trust had a 5.22% return in February, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares.
- 03/03/2024
|
Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
- Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
- 02/27/2024
|
1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now
- Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock. It's also been incredibly profitable for its shareholders since its spinoff from Pfizer.
- 02/26/2024
|
5 Dividend Growth Stocks That Outperformed S&P 500 Over 5-Year Rolling Periods
- Beating the S&P 500 is difficult due to skewed market returns favoring a few high-performing stocks.
- 02/19/2024
|
GRFS or ZTS: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
- 02/14/2024
|
Zoetis CEO Kristin Peck on Q4 earnings
- Kristin Peck, Zoetis CEO, joins 'Money Movers' to discuss what Zoetis' guidance says about Peck's business expectations, factors that are contributing to their growth relative to fundamentals, and how consumers are thinking about their pets.
- 02/13/2024
|
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
- Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
- 02/13/2024
|
Compared to Estimates, Zoetis (ZTS) Q4 Earnings: A Look at Key Metrics
- The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/13/2024
|
Zoetis (ZTS) Q4 Earnings Lag Estimates
- Zoetis (ZTS) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $1.15 per share a year ago.
- 02/13/2024
|
Ahead of Zoetis (ZTS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 02/08/2024
|
Daily Dividend Report: Mastercard, MMM, Gilead, Keurig, Zoetis
- Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A common stock and Class B common stock as of April 9, 2024.
- 02/07/2024
|
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
- Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/06/2024
|
GRFS or ZTS: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 01/29/2024
|
4 Magnificent Stocks I'm Done Waiting on a Dip for in 2024 -- but I'm Not Buying Them Hand Over Fist, Either
- Celsius brings triple-digit sales growth with newfound profitability. Cintas and Rollins are home to products you don't know you love until you don't have them.
- 01/20/2024
|
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
- Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/15/2024
|
GRFS vs. ZTS: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 01/12/2024
|
Zoetis CFO on animal health trends and using AI for medicine
- Zoetis CFO Wetteny Joseph discusses growth in the animal health care sector.
- 01/12/2024
|
5 Upcoming Dividend Increases
- 5 Upcoming Dividend Increases
- 01/12/2024
|
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
- Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
- 01/09/2024
|
My Top 15 High Growth Dividend Stocks For January 2024
- The SPDR S&P 500 ETF was up 4.57% in December, Vanguard's Dividend Appreciation ETF was up 4.13%, and my watchlist beat both with a return of 9.52%.
- 01/02/2024
|
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2023 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/eve.
- 12/28/2023
|
GRFS or ZTS: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
- 12/27/2023
|
Pet Care Profits: 3 Stocks Benefitting from the Pet Boom
- Pet care stocks are incredibly effective in diversifying investment portfolios, leveraging the robust growth of the pet care industry. The sector's expansion is evident.
- 12/26/2023
|
Forever Favorites: 7 Dividend Stocks to Buy and Never Sell
- Some investments just look after themselves. They are “set it and forget it” kind of stocks.
- 12/19/2023
|
Our Top 10 Dividend Growth Stocks - December 2023
- We focus on selecting high-growth dividend stocks that have rapidly grown their dividends in the recent past rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. We provide criteria for selecting high-growth dividend stocks and offer a step-by-step guide on structuring a portfolio based on this strategy.
- 12/16/2023
|
4 Stocks to Watch That Recently Declared Dividend Hikes
- Invitation Homes Inc. (INVH), Choice Hotels International, Inc. (CHH), Zoetis Inc. (ZTS) and Owens Corning (OC) recently announced dividend hikes.
- 12/11/2023
|
3 Promising Stocks to Buy in the Booming Pet Tech Industry
- Pet stocks are an exciting way to diversify your portfolio. These companies ride high on the tailwinds of the pet care industry, which took many analysts by surprise.
- 12/07/2023
|
My Top 15 High Growth Dividend Stocks For December 2023
- The SPDR S&P 500 ETF was up 9.13% in November, Vanguard's Dividend Appreciation ETF was up 7.47%, my watchlist beat both with a return of 10.24%. The top 15 dividend growth stocks for December offer an average dividend yield of 1.99% and appear to be about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is rocking a cool 11.76% annualized return, beating VIG by 2.36% and SPY by 1.52%.
- 12/03/2023
|
3 Pet Care Stocks to Capitalize on the Animal Economy
- Most recent data shows that 66% of U.S. households own a pet. Another interesting point is that “85% of dog owners and 76% of cat owners consider their pets to be a member of the family.
- 11/22/2023
|
My Top 15 High Growth Dividend Stocks For November 2023
- The SPDR S&P 500 ETF posted its third consecutive losing month in October, the first time this has happened since I started tracking this series in September 2020. The top 15 dividend growth stocks for November offer an average dividend yield of 1.90% and appear to be about 40% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is outperforming VIG by 1.49% and SPY by 1.18%, on an annualized basis.
- 11/03/2023
|
Here's What Key Metrics Tell Us About Zoetis (ZTS) Q3 Earnings
- While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 11/02/2023
|
Zoetis CEO on Q3 earnings: We keep seeing the resilience of the animal health sector amid downturns
- Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss her insights into livestock and pet care products, how tied Zoetis' business is to the macro economy, and more.
- 11/02/2023
|
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
- 10/26/2023
|
Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now
- Zoetis is an animal health company specializing in the development and manufacturing of veterinary pharmaceuticals and vaccines for both livestock and companion animals. For FY2023, the company has announced a $1 billion investment to enhance manufacturing capacity for monoclonal antibodies. This is the largest investment in its history. The company is sacrificing the short term to benefit in the long term. Which seems like a great decision and demonstrates an amazing corporate culture.
- 10/26/2023
|
Our Top 10 Picks For Dividend Growth Stocks - October 2023
- We pick high-growth dividend stocks that have rapidly grown their dividends in the recent past rather than offering a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. We provide criteria for selecting high-growth dividend stocks, offering a step-by-step guide on structuring a portfolio based on this strategy.
- 10/21/2023
|
The Top 7 Stocks to Own During a Downturn
- As uncertainty seems to dominate, it might be time to look for stocks to own during a downturn. For 10 straight months, investors enjoyed a strong comeback rally in the S&P 500.
- 10/11/2023
|
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 10/10/2023
|
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
- Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/06/2023
|
Which Is A Better Pick – Keurig Dr Pepper Stock Or Zoetis?
- We believe that Zoetis stock (NYSE: ZTS), an animal health company, is a better pick than Keurig Dr Pepper stock (NASDAQ: KDP), given its better prospects.
- 09/27/2023
|
Zoetis Is An Impressive Healthcare Compounder
- Zoetis Inc., the world's largest provider of animal medicines, vaccines, and diagnostic products, is capitalizing on the growing trend of pet pampering. The company dominates the companion animal and cattle markets, which are anti-cyclical and have strong growth potential. Zoetis expects to sustain above-average growth through innovation, strategic investments, and leveraging its broad product portfolio.
- 09/26/2023
|
Our Top 10 Picks For Dividend Growth Stocks - September 2023
- This monthly series of articles focuses on DGI stocks likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.
- 09/17/2023
|
USNA vs. ZTS: Which Stock Is the Better Value Option?
- Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
- 09/13/2023
|
Zoetis to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:55 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-pr.
- 09/06/2023
|
My Top 15 High Growth Dividend Stocks For September 2023
- The summer stock market rally ended in August, with the SPDR S&P 500 Trust ETF posting a loss of 1.63%. The top 15 dividend growth stocks for September offer an average dividend yield of 1.86% and appear about 36% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 3.91% and SPY by 3.12%.
- 09/04/2023
|
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
- 08/28/2023
|
Zoetis' (ZTS) Companion Animal Products to Boost Revenues
- Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.
- 08/23/2023
|
Our Top 10 Picks For Dividend Growth Stocks - August 2023
- This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks and offers a step-by-step guide on how to structure a portfolio based on this strategy.
- 08/19/2023
|
USNA or ZTS: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
- 08/10/2023
|
Zoetis CEO Kristin Peck on Q2 earnings results, state of animal health care
- Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss what the company's guidance was largely driven by, the most important aspect of Zoetis' business, and how new GLP-1 drugs could play into Zoetis' business.
- 08/08/2023
|
Zoetis Inc. (ZTS) Q22023 Earnings Call Transcript
- Zoetis Inc. (NYSE:ZTS ) Q22023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Louise Chen - Cantor Operator Welcome to the Second Quarter 2023 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
- 08/08/2023
|
Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say
- The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/08/2023
|
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
- Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.
- 08/08/2023
|
Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates
- Zoetis (ZTS) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.20 per share a year ago.
- 08/08/2023
|
My Top 15 High Growth Dividend Stocks For August 2023
- The watchlist from July posted a gain of 5.36% last month, outperforming the SPDR S&P 500 Trust ETF and Vanguard's Dividend Appreciation ETF. The top 15 dividend growth stocks for August offer an average dividend yield of 1.58% and appear about 32% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 5.24% and SPY by 4.53%.
- 08/05/2023
|
Rising Dividend Make Zoetis a Doggone Winner
- When Zoetis Inc. NYSE: ZTS reports second-quarter financials next week, the market will be expecting its best revenue growth in a year and a 9% jump in profits. If history repeats, the results will be even better.
- 08/03/2023
|
2 Healthcare Stocks That Could Make You Richer
- As a producer of medicines for animals, Zoetis benefits from increased spending on pets. Thanks to a strong product line, Eli Lilly briefly ranked as the biggest pharma company this year.
- 07/29/2023
|
Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?
- Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/24/2023
|
Our Top 10 Picks For Dividend Growth Stocks - July 2023
- This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. A balanced portfolio should have a mix of high-dividend growth stocks and high-yield dividend stocks, depending on the life stage. If you are in the accumulation phase and are several years away from retirement, high-growth dividend stocks would be more appropriate for long-term growth.
- 07/22/2023
|
Zoetis: My Dog Approves Of This Dividend Compounder
- Zoetis: My Dog Approves Of This Dividend Compounder
- 07/19/2023
|
2 Dividend Stocks That Doubled Their Payouts in 5 Years
- Zoetis and Mastercard don't offer high yields, but both aggressively raised their payouts in recent years. Both companies have modest payout ratios, suggesting more hikes could be on the way.
- 07/19/2023
|
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/11/2023
|
Wall Street Analysts Believe Zoetis (ZTS) Could Rally 27.94%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/05/2023
|
My Top 15 High Growth Dividend Stocks For July 2023
- The watchlist from June posted a gain of 8.91% last month, outperforming the SPDR S&P 500 Trust ETF by 2.43% and Vanguard's Dividend Appreciation ETF by 2.41%. The top 15 dividend growth stocks for July offer an average dividend yield of 1.66% and appear about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 4.20% and SPY by 3.81%.
- 07/03/2023
|
Zoetis to Host Webcast and Conference Call on Second Quarter 2023 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentatio.
- 06/30/2023
|
Zoetis (ZTS) Just Reclaimed the 20-Day Moving Average
- After reaching an important support level, Zoetis (ZTS) could be a good stock pick from a technical perspective. ZTS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
- 06/28/2023
|
There Are Plenty of Reasons to Like Zoetis
- Zoetis Inc. ( ZTS , Financial) is a leading animal health company with a diversified product portfolio of medicines and vaccines that aim to treat and protect livestock and companion animals.
- 06/27/2023
|
Zoetis: A Purrfect Addition To Your Portfolio
- Zoetis, a global leader in the animal health industry, has beaten the S&P 500 over the last five years and offers diverse growth opportunities. The company has a strong international presence, a commitment to innovation, and a focus on key growth areas such as dermatology, parasiticides, pain, diagnostics, and emerging markets. Despite a high valuation and significant debt, Zoetis is a high-quality business that could reward patient, long-term investors.
- 06/22/2023
|
History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever
- Zoetis has more than doubled the S&P 500's return over the past decade. The animal health company's return on invested capital has risen to over 18%.
- 06/21/2023
|
My Top 15 High Growth Dividend Stocks For June 2023
- I present my top 15 high-growth dividend stocks to consider during the month of June. The watchlist underperformed VIG in May, but continues to outpace the ETF year-to-date and since inception. Five new stocks have been added to the watchlist for June: Intuit, Mastercard, Microchip Technology Inc., Sirius XM Holdings, and Skyworks Solutions.
- 06/03/2023
|
Zoetis' Dividend Growth: Small Yield, Big Returns
- The article discusses Zoetis, a low-yielding dividend stock with high dividend growth potential. Zoetis is the world's leading producer of medicine and vaccinations for pets and livestock, with a global footprint of over 100 markets and more than 70 years of experience.
- 05/10/2023
|
Zoetis (ZTS) Q1 Earnings Top Estimates
- Zoetis (ZTS) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.32 per share a year ago.
- 05/04/2023
|
Zoetis Tumbles As Spot's Drugmaker Reports Mixed Earnings, Though Keeps Outlook
- Animal health behemoth Zoetis reported a mixed first quarter but kept its full-year outlook. Still, ZTS stock tumbled early Thursday.
- 05/04/2023
|
Zoetis Stock Falls Amid Mixed Earnings Report
- The animal health provider maintained its guidance for full year 2023 after first quarter earnings beat expectations.
- 05/04/2023
|
My Top 15 High-Growth Dividend Stocks For May 2023
- I present my top 15 high-growth dividend stocks to consider during the month of May. The watchlist posted a gain of 0.41% in April, trailing both VIG and SPY.
- 05/01/2023
|
Zoetis Announces Date for 2023 Investor Day
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team. Zoetis will provide an update on the company's strategy to deliver long-term profitable growth and value for shareholders, followed by a Q&A session. The.
- 05/01/2023
|
5 Women-Led Businesses Absolutely Crushing the Stock Market Right Now
- Women hold a tiny fraction of the CEO jobs at America's biggest companies. That number is steadily increasing.
- 04/30/2023
|
Why These 2 Vet Med Stocks Are Surging
- Nearly 87 million households -- over two-thirds of the total -- own at least one pet. Spending on pet healthcare could nearly double by 2030 to $112 billion.
- 04/28/2023
|
3 Pet Stocks That Could Purr in 2023 and Beyond
- Animal-loving investors may be interested in exploring opportunities in the pet industry. While there are altruistic reasons for supporting companies that focus on the well-being of our furry friends, pet stocks have also seen impressive growth over the past decade, which was accelerated by the pandemic.
- 04/24/2023
|
ALPMY or ZTS: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Drugs stocks are likely familiar with Astellas Pharma Inc. (ALPMY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
- 04/18/2023
|
2 Pet Stocks Poised to Benefit From Industry Growth
- During the pandemic lockdowns, adopting pets became popular, resulting in a whopping 5 million more pets being added to households in the U.S. Morgan Stanley predicts that the overall spending in the pet industry will grow at a compounded annual growth rate of 8% and will be worth $277 billion by 2030, reaching $1,320 per pet per household in 2025 and $1,897 by 2030. Thus, let's take a look at two industry-leading stocks poised to benefit from this trend.
- 04/12/2023
|
Zoetis: Great Business, Fair Price
- Peter Drucker, who is widely considered the father of modern management, famously said that a business only has two basic functions and Zoetis is thriving on both these fronts. Numbers continue to trend in the right direction despite looming threats on the horizon.
- 04/06/2023
|
My Top 15 High-Growth Dividend Stocks For April 2023
- I present my top 15 high-growth dividend stocks to consider during the month of April. The watchlist posted a gain of 2.02% in March, finishing ahead of VIG but trailing SPY.
- 04/03/2023
|
3 Healthcare Stocks to Watch As the Industry Evolves
- In 2022, healthcare stocks surpassed the S&P 500. But in 2023, they are not doing so well.
- 03/31/2023
|
Analysts Agree Now's The Time To Buy These 10 Promising Stocks
- Finding S&P 500 stocks that analysts agree on is rare. So when you see nearly unanimous agreement on some, that's quite a statement.
- 03/28/2023
|
3 Awesome Dividend Growth Stocks To Buy During A Bear Market
- Markets are in turmoil. Hence, in this article, we start with a discussion of the risks facing investors and why I believe in attractive buying opportunities this year. While I understand that investors often opt for higher-yielding investments, I will explain why investments in low-yielding dividend-growth stocks come with benefits.
- 03/14/2023
|
My Top 15 High-Growth Dividend Stocks For March 2023
- I present my top 15 high-growth dividend stocks to consider during the month of March. The watchlist posted loss of 2.94% in February, finishing behind VIG and SPY on the month.
- 03/02/2023
|
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
- COLL vs. ZTS: Which Stock Is the Better Value Option?
- 03/01/2023
|
Final Trades: Arista Networks, Zoetis, Alaska Air & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 02/24/2023
|
Why Zoetis Stock Shot Almost 9% Higher This Week
- Robust net-income growth and better-than-expected guidance brought the bulls back to the animal health specialist.
- 02/17/2023
|
Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
- The stock is up 7.99 in the past week, after topping fourth-quarter views in its February 14 report. It also guided toward robust sales this year.
- 02/16/2023
|
Final Trades: Zoetis, Citigroup & Nvidia
- The "Halftime Report" traders give their top picks to watch for the second half.
- 02/14/2023
|
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat
- Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
- 02/14/2023
|
Zoetis Inc. (ZTS) Q4 2022 Earnings Call Transcript
- Zoetis Inc. (NYSE:ZTS ) Q4 2022 Earnings Conference Call February 14, 2023 8:30 AM ET Company Participants Steve Frank - Vice President, Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley Louise Chen - Cantor Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Chris Schott - JPMorgan Brandon Vazquez - William Blair Elliot Wilbur - Raymond James Operator Welcome to the Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
- 02/14/2023
|
Zoetis (ZTS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/14/2023
|
Zoetis (ZTS) Matches Q4 Earnings Estimates
- Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/14/2023
|
Zoetis Snags A Quarterly Sales Beat And Issues A Strong 2023 Outlook
- Animal health giant Zoetis beat fourth-quarter sales expectations Tuesday and issued a strong 2023 outlook, leading ZTS stock to pop. The post Zoetis Snags A Quarterly Sales Beat And Issues A Strong 2023 Outlook appeared first on Investor's Business Daily.
- 02/14/2023
|
COLL or ZTS: Which Is the Better Value Stock Right Now?
- COLL vs. ZTS: Which Stock Is the Better Value Option?
- 02/13/2023
|
3 Stocks to Avoid This Week
- These investments seem pretty vulnerable right now.
- 02/13/2023
|
My Top 15 High-Growth Dividend Stocks For February 2023
- I present my top 15 high-growth dividend stocks to consider during the month of February. The watchlist posted a gain of 9.44% in January and starts the new year on a positive note.
- 02/02/2023
|
4 Top Stocks With High Dividend Growth to Buy in 2023 and Hold Forever
- These businesses offer powerful passive income potential, growing their dividends between 178% and 481% over the last five years.
- 01/28/2023
|
UTHR vs. ZTS: Which Stock Is the Better Value Option?
- UTHR vs. ZTS: Which Stock Is the Better Value Option?
- 01/27/2023
|
3 Reasons to Buy Zoetis, and 1 Reason to Sell
- This stock is a proven long-term play, but it's struggling lately.
- 01/17/2023
|
Top 10 Dividend Growth Stocks For January 2023
- This article will focus on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. High-growth dividend stocks are particularly suited for folks who are in the accumulation phase and are several years away from retirement.
- 01/17/2023
|
3 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 9.6% and a median increase of 11.9%.
- 01/12/2023
|
Why Zoetis Stock Lost 40% in 2022
- Sluggish growth and multiple headwinds weighed on the stock.
- 01/11/2023
|
Final Trades: Abbott Labs, SL Green, Zoetis & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/11/2023
|
COLL vs. ZTS: Which Stock Is the Better Value Option?
- COLL vs. ZTS: Which Stock Is the Better Value Option?
- 01/11/2023
|
Zoetis CEO Kristin Peck on veterinary workforce challenges and recession resilience of pet industry
- Kristin Peck, CEO of Zoetis, joins 'The Exchange' to discuss the pandemic pet boom, demographic shifts among pet owners, and the labor capacity issues associated with veterinary services.
- 01/10/2023
|
It's A Great Time To Buy Zoetis Shares
- Zoetis has a very strong competitive moat resulting from its patents, scale, and respected brands. It has been delivering above-market growth for many years, and its profit margins have been on an upward trend.
- 01/09/2023
|
The 7 Most Undervalued Value Stocks to Buy Now
- Investors are entering a new era that could very well be dominated by value investing for quite some time. As a result, investors should look for undervalued value stocks to buy now.
- 01/08/2023
|
Is Zoetis Stock a Buy?
- Zoetis' business is generally stable and very consistent -- but the same can't be said for its struggling stock.
- 01/05/2023
|
Mutual Funds Are Investing In 'Survivors' For 2023
- Stock picking is an art in a tough market. Learn which companies mutual fund managers believe can grow during economic uncertainty.
- 12/30/2022
|
Tesla is not alone: 18 (and a half) other big stocks are headed for their worst year on record
- In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.
- 12/29/2022
|
7 Long-Term Stocks to Put on Your Buy List in 2023
- 2022 wasn't a banner year for most investors. Major American equity markets fell into bear market territory.
- 12/29/2022
|
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 12/26/2022
|
2 Beaten-Down Industry-Leading Stocks to Buy and Hold
- These companies' recent stock market performances don't tell the whole story.
- 12/26/2022
|
Zoetis CEO on egg price increases
- Cramer spoke with Zoetis CEO Kristin Peck on Thursday.
- 12/22/2022
|
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2022 Financial Results
- PARSIPPANY, N.J.--( BUSINESS WIRE )--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 14, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2022 financial results and respond to questions from financial analysts during the call.
- 12/22/2022
|
3 Beaten-Down Stocks That Could Explode Higher in 2023
- These stocks could have significant upside opportunities ahead.
- 12/17/2022
|
JPMorgan's bullish call on biopharma
- The "Halftime Report" traders debate the biggest analyst calls of the day.
- 12/16/2022
|
7 Best Bargain Stocks to Buy in 2023
- 2022 was a year of soaring consumer prices and falling stock prices. I'm sure most investors will be happy to put it behind them, perhaps after some tax-loss harvesting.
- 12/13/2022
|
11% Of S&P 500 Stocks Suffer Their Worst Year Ever
- Tesla isn't the only stock that's struggling in 2022. Nearly 60 S&P 500 stocks — or about 11% — are having their worst year ever.
- 11/28/2022
|
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 11/23/2022
|
Families are adopting, spending more on pets amid pandemic: Zoetis CEO
- Shelters have seen pet adoptions increase 15% year over year. As Americans spend more time at home with their companions, it has led to more spending on pet care, animal pharmaceuticals provider Zoetis CEO Kristin Peck explained.
- 11/19/2022
|
Pet adoption theme will continue, says petcare company Zoetis' CEO
- Pet care company Zoetis beat on the top and bottom lines after reporting earnings this morning. The company is seeing strong momentum for 2021, despite pandemic uncertainty.
- 11/19/2022
|
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 11/07/2022
|
2 Pet Medicine Stocks That Make Great Long-Term Investments
- Two of the biggest names in animal care continue to grow.
- 11/07/2022
|
Why Zoetis Stock Was Falling Today
- The animal healthcare company missed estimates in its third-quarter earnings report.
- 11/03/2022
|
Demand for animal medicine remains fundamentally strong, says Zoetis CEO Kristin Peck
- Zoetis CEO Kristin Peck joins 'Closing Bell' to discuss Zoetis stocks dropping after a worse than expected earnings report, the supply constraints that has been adding pressure to key growth drivers, and the demand outlook for 2023.
- 11/03/2022
|
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
- Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market.
- 11/03/2022
|
Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates
- Zoetis (ZTS) delivered earnings and revenue surprises of -2.42% and 3.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
- Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.
- 10/31/2022
|
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
- JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- 10/20/2022
|
Daily Dividend Report: McDonald's, Qualcomm, Agree Realty, Zoetis, NextEra Energy
- Daily Dividend Report: McDonald's, Qualcomm, Agree Realty, Zoetis, NextEra Energy
- 10/14/2022
|
A Rising Dollar May Mean Lower Zoetis Shares
- While investors may be tempted to buy into Zoetis given its weakness this year, there is likely further downside. The livestock business has seen revenue decline due to generics competition and favorable tailwinds in companion animals may be fading.
- 10/07/2022
|
Zoetis to Host Webcast and Conference Call on Third Quarter 2022 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #fortune500--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 3, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2022 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentatio
- 09/29/2022
|
2 Stocks to Buy Near Their 52-Week Lows
- Let's not forget one of the first rules of investing: Buy low.
- 09/24/2022
|
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 09/21/2022
|
Zoetis to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:05 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events
- 09/09/2022
|
TAK or ZTS: Which Is the Better Value Stock Right Now?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 09/05/2022
|
5 Pet Care Stocks Gurus Love
- Despite inflationary pressures that are increasing the price of goods across the board, consumers are still pampering their pets when it comes to food.
- 09/02/2022
|
3 Dividend Stocks That Have Made Monster-Size Rate Hikes This Year
- These stocks have all raised their dividend payments by at least 30% within the past 12 months.
- 08/25/2022
|
Frank Sands' Top New Tech Buys
- Sands Capital Management recently disclosed its 13F portfolio updates for the second quarter of 2022, which ended on June 30.
- 08/22/2022
|
TAK vs. ZTS: Which Stock Is the Better Value Option?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 08/19/2022
|
Zoetis: Strong Q2 Underlying Growth But Hit By Strong U.S. Dollar
- Zoetis released Q2 results last Thursday, and shares have fallen another 4% since, to 31% below their December 2021 peak. Net Income was flat year-on-year in Q2, but primarily due to currency. Operationally, revenues grew 8% and Net Income grew 9%.
- 08/12/2022
|
The 'recession-resistant' market that may have investors rolling over
- Zoetis CFO Wetteny Joseph joins Yahoo Finance Live to discuss earnings and the market for pet health and spending.
- 08/05/2022
|
These Are The Ten Biggest Companies With Over 90% Institutional Ownership
- Institutional investors are big investors that generally buy shares on behalf of their clients or members.
- 08/04/2022
|
Trends in pet care are driven by younger people getting pets, says Zoetis CEO
- Kristin Peck, Zoetis CEO, joins 'Closing Bell' to discuss the company's quarterly earnings results, the market reaction and how inflation is impacting Zoetis.
- 08/04/2022
|
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
- Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
- 08/04/2022
|
Zoetis Trims Full-Year Outlook Following Mixed Second Quarter
- Zoetis narrowly missed quarterly earnings estimates, though sales came in above forecasts. But Zoetis trimmed its outlook and ZTS stock fell.
- 08/04/2022
|
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 08/03/2022
|
Zoetis: Lovable Company With Vision
- Zoetis is a global leader of Animal Healthcare products. They have a diverse and durable portfolio consisting of medicines, vaccines, diagnostics, and genetics.
- 07/20/2022
|
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 07/18/2022
|
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
- Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/14/2022
|
Final Trades: Delta, Zoetis & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 07/08/2022
|
3 Best Farming Stocks to Buy
- While prices at the grocer continue to soar, today investors have a chance to buy three of the market's best farming stocks on the cheap! The post 3 Best Farming Stocks to Buy appeared first on InvestorPlace.
- 07/08/2022
|
Zoetis to Host Webcast and Conference Call on Second Quarter 2022 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 4, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2022 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentati
- 06/30/2022
|
ASRT or ZTS: Which Is the Better Value Stock Right Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 06/29/2022
|
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 06/13/2022
|
Zoetis to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 4:20 p.m. ET (1:20 p.m. PT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.co
- 06/10/2022
|
Mosaic Company Or Zoetis Inc.: Which Is A Buy In The Array Of Agribstocks
- The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients in North America and internationally. It owns and operates mines, which produce concentrated phosphate crop. Institutions hold 90% of shares, insiders less than 0.1%, and may ignore dividends yielding 1% yearly. Prior price range forecasts at today's reward~risk ratios net-realized 42% CAGRs.
- 06/06/2022
|
Final Trades: Zoetis, Costco, Disney & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 05/27/2022
|
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 05/26/2022
|
Zoetis: Animal Health Leader Now Cheapest Since April 2021
- Zoetis: Animal Health Leader Now Cheapest Since April 2021
- 05/20/2022
|
Vanguard Health Care Fund's Top 5 Trades in the 1st Quarter
- The Vanguard Health Care Fund (Trades, Portfolio) recently disclosed its first quarter 2022 portfolio, revealing that its top five trades for the quarter included a new position in Zoetis Inc. ( ZTS , Financial), a boost to its holding in Daiichi Sankyo Co. Ltd. ( TSE:4568 , Financial), the closure of its position in Elanco Animal Health Inc. ( ELAN , Financial) and reductions to its holdings in Bristol-Myers Squibb Co. ( BMY , Financial) and Anthem Inc. ( ANTM , Financial).
- 05/09/2022
|
7 Defensive Dividend Healthcare Stocks to Buy Now
- As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.
- 05/06/2022
|
Zoetis Inc. (ZTS) CEO Kristin Peck on Q1 2022 Results - Earnings Call Transcript
- Zoetis Inc. (NYSE:ZTS ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Steve Frank - VP, IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Erin Wright - Morgan Stanley Christine Rains - William Blair Louise Chen - Cantor Nathan Rich - Goldman Sachs Michael Ryskin - Bank of America Jon Block - Stifel Balaji Prasad - Barclays Chris Schott - JPMorgan Steve Scala - Cowen Elliott Wilbur - Raymond James Operator Welcome to the First Quarter 2022 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
- 05/05/2022
|
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
- Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.
- 05/05/2022
|
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
- Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
- Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
- 05/04/2022
|
Final Trades: Zoetis, Occidental, Paramount & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 05/02/2022
|
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
- Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
- 05/02/2022
|
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2022
|
Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)
- Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/20/2022
|
Why You Might Want To Add Zoetis To Your Portfolio
- In an inflationary environment, you want to be in companies with strong pricing power such as Zoetis. The company is well managed and has been growing at a very decent pace, it pays a small dividend but earnings growth has been solid.
- 04/13/2022
|
COLL or ZTS: Which Is the Better Value Stock Right Now?
- COLL vs. ZTS: Which Stock Is the Better Value Option?
- 04/06/2022
|
COLL or ZTS: Which Is the Better Value Stock Right Now?
- COLL vs. ZTS: Which Stock Is the Better Value Option?
- 03/21/2022
|
Zoetis to Participate in the Barclays Global Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2022.
- 03/11/2022
|
Down 9% In A Month, Will Zoetis Stock Rebound?
- The stock price of Zoetis, an animal health company, has seen a 9% fall in a month, while it is down 6% in a week. The company reported upbeat Q4 results last month, with revenue of $2.0 billion and adjusted EPS of $1.00, beating the consensus estimates of $1.9 billion and $0.96, respectively.
- 03/10/2022
|
Librarian Capital's Monthly Top Buys And Price Moves - March 2022
- Librarian Capital's Monthly Top Buys And Price Moves - March 2022
- 03/03/2022
|
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
- The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. The post 3 Beaten-Down Growth Stocks With More Than 50% Upside Potential appeared first on InvestorPlace.
- 02/25/2022
|
Russia-Ukraine Tensions Escalate: 3 ETFs to Buy
- Russian aggression against Ukraine has sent commodities and gold higher
- 02/23/2022
|
Zoetis: Upgrade To Buy After 22% Fall From Peak And Strong Q4
- We upgrade our rating on Zoetis to Buy, after shares have fallen 22% from their peak, to below the level at our downgrade 7 months ago. Zoetis is a high-quality business capable of a 10%+ EPS CAGR long term. Its trailing P/E is now 41.2x, compared to 51.8x at our downgrade.
- 02/18/2022
|
People are spending more time and money on their pets, says Zoetis CEO Kristin Peck
- Zoetis CEO Kristin Peck joined 'Closing Bell' to discuss the company's 4th quarter sales and the strength of pet products.
- 02/16/2022
|
Zoetis Inc. (ZTS) CEO Kristin Peck on Q4 2021 Results - Earnings Call Transcript
- Zoetis Inc. (ZTS) CEO Kristin Peck on Q4 2021 Results - Earnings Call Transcript
- 02/15/2022
|
Zoetis tops earnings estimates and offers upbeat revenue guidance, shares up 1.5% premarket
- Animal health company Zoetis Inc.'s shares ZTS, -1.23% jumped 1.5% premarket Tuesday, after it beat estimates for the fourth quarter and offered upbeat revenue guidance for 2022. The company posted net income of $414 million, or 87 cents a share, for the quarter, up from $359 million, or 75 cents a share, in the year-earlier period.
- 02/15/2022
|
Top 5 Stocks to Buy on the Dip Despite Market Fluctuations
- We have narrowed our search to five U.S. corporate giants (market capital > $50 billion) that are currently trading on the dip. These are: TSLA, GM, FDX, MRVL and ZTS.
- 01/31/2022
|
2 Stocks That Could Turn $250,000 Into $1,000,000 By 2032
- Both of these companies are leaders in their respective industries.
- 01/23/2022
|
7 of the Top-Rated Pharmaceutical Stocks for Q1
- As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace.
- 01/18/2022
|
FDA Approves Zoetis' Solensia To Control Osteoarthritis Pain In Cats
- The FDA has approved Zoetis Inc's (NYSE: ZTS) Solensia (frunevetmab injection) to control the pain of osteoarthritis (OA) in cats, helping improve their mobility, comfort, and overall well-being. Solensia, prescribed as a once-monthly injection administered in the veterinary clinic, controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain.
- 01/14/2022
|
Zoetis Has A Giant Upcoming Dividend Increase
- Zoetis Has A Giant Upcoming Dividend Increase
- 01/14/2022
|
Why Zoetis Stock Gained 47% in 2021
- The animal health company delivered strong results over the year.
- 01/12/2022
|
Zoetis CEO says the animal health company is stepping up its spending on consumer advertising
- Zoetis CEO Kristin Peck appeared on Tuesday's episode of "Mad Money," discussing the company's spending on direct-to-consumer advertising and efforts to maintain attractive prices for its products.
- 01/11/2022
|
Here's Why Zoetis (ZTS) is Poised for a Turnaround After Losing 8.8% in 4 Weeks
- Zoetis (ZTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 01/10/2022
|
CORT vs. ZTS: Which Stock Is the Better Value Option?
- CORT vs. ZTS: Which Stock Is the Better Value Option?
- 01/05/2022
|
4 Top Stock Trades for Wednesday: AVGO, AMD, ARKK, ZTS
- Advanced Micro Devices, Broadcom, the ARKK ETF and Zoetis were our top stock trades for Wednesday. Now, let's take a look at the charts.
- 01/04/2022
|
Librarian Capital's Monthly Top Buys And Price Moves - January 2022
- Tobacco stocks remain strong buys after the defeat of the U.S. "nicotine tax" proposal and a reassuring update from British American Tobacco. In Payment, Mastercard and Visa each rebounded by more than 10%; U.S. holiday retail sales were strong and credit cards kept growing.
- 01/04/2022
|
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2021 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis will report Q4 and full year 2021 financial results on Tuesday, Feb. 15, 2022.
- 12/23/2021
|
CVS, Abbot, and Other Companies That Raised Their Dividends This Week
- Zoetis, Pentair, Johnson Controls International, and Abbott Laboratories were among the many companies that declared dividend increases this week.
- 12/12/2021
|
Zoetis, CVS Health, and Other Companies That Raised Their Dividends
- Zoetis, Pentair, Johnson Controls International, and Abbott Laboratories were among the many companies that declared dividend increases this week.
- 12/11/2021
|
Quieter Session Allows Indexes Digest Gains; EPAM, Cadence And Zoetis In Focus
- Quieter Session Allows Indexes Digest Gains; EPAM, Cadence And Zoetis In Focus Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market. Learn more.
- 12/08/2021
|
Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of $3.5B
- The board of directors of Zoetis Inc (NYSE: ZTS) has approved a $3.5 billion share repurchase program. The company added that the new share buyback, spanning across a multi-year period, could be canceled at any time.
- 12/08/2021
|
4 Large-Cap Stocks With High Returns on Equity
- When a company's return on equity (ROE) ratio is better than most of its competitors, it generally indicates that the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks, as they are performing better than most of their peer group companies in terms of a higher ROE ratio.
- 11/28/2021
|
Animal care: People are ‘investing more in their pets' wellness,' Zoetis CFO says
- Zoetis CFO Wetteny Joseph joins Yahoo Finance's Emily McCormick to discuss Q3 earnings, global trends for pet health care, and COVID vaccines for animals. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb179GLPNYE Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
- 11/08/2021
|
There's a 'long tail' to Zoetis' growth, CEO believes
- Kristin Peck, Zoetis CEO, joins 'Closing Bell' to give a candid look at the company's Q3 earnings results and where Zoetis has seen steady, durable growth. Peck says they're on track for the company's best year and goes on to explain why she believes they'll continue to do well.
- 11/04/2021
|
Zoetis Inc. (ZTS) CEO Kristin Peck on Q3 2021 Results - Earnings Call Transcript
- Zoetis Inc. (ZTS) CEO Kristin Peck on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3
- Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.
- 11/04/2021
|
Zoetis (ZTS) Beats Q3 Earnings and Revenue Estimates
- Zoetis (ZTS) delivered earnings and revenue surprises of 13.64% and 2.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
- Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/03/2021
|
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
- Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.
- 11/01/2021
|
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
- Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
- 10/29/2021
|
ETO: A Solid Dividend Fund But Expensive
- ETO: A Solid Dividend Fund But Expensive
- 10/27/2021
|
Zoetis: Expensive But Precision Livestock Farming Division Could Be Game Changer
- Zoetis is the leader in pharmaceutical drugs, nutrition, and diagnostics for companion animals and livestock.
- 10/26/2021
|
Zoetis Announces Appointment of Robert J. Polzer, PhD, as President of Research & Development for World Leader in Animal Health
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #ResearchandDevelopment--Robert J. Polzer, PhD, will succeed current EVP and President of R&D at Zoetis, Dr. Catherine Knupp, DVM, MS.
- 10/18/2021
|
Zoetis to Host Webcast and Conference Call on Third Quarter 2021 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis Inc. will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021.
- 09/30/2021
|
Zoetis Named a “100 Best Company” and a “Best Company for Dads” by Seramount
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Seramount100Best2021--Zoetis Named a “100 Best Company” and a “Best Company for Dads” by Seramount.
- 09/28/2021
|
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
- COLL vs. ZTS: Which Stock Is the Better Value Option?
- 09/20/2021
|
Zoetis to Participate in the Jefferies Virtual Pet Care Summit
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to present at the Jefferies Virtual Pet Care Summit on Thursday, Sept. 16th.
- 09/13/2021
|
Final Trades: Bristol Myers, Marathon Petroleum, Zoetis & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 09/08/2021
|
7 Best Bear Market Stocks to Buy Now in Preparation for a Downturn
- These seven stocks to buy right now for a bear market are also generally strong in bull markets. Their resistance is the key element.
- 08/11/2021
|
Zoetis, Inc Among This Week's U.S. Large Caps Stocks
- Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Zoetis, Inc among others.
- 08/10/2021
|
Zoetis CEO on Q2 results: “trends in companion animal are durable”
- Zoetis Inc. (NYSE: ZTS) reported its financial results for the second quarter on Thursday that beat Wall Street estimates. The stock was largely unbothered in after-hours trading despite raised guidance for the full year.
- 08/05/2021
|
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
- Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.
- 08/05/2021
|
Zoetis Inc. (ZTS) CEO Kristin Peck on Q2 2021 Results - Earnings Call Transcript
- Zoetis Inc. (ZTS) CEO Kristin Peck on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Zoetis (ZTS) Surpasses Q2 Earnings and Revenue Estimates
- Zoetis (ZTS) delivered earnings and revenue surprises of 10.19% and 6.30%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
- Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
- 08/04/2021
|
Why Earnings Season Could Be Great for Zoetis (ZTS)
- Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/04/2021
|
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
- Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.
- 08/02/2021
|
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
- We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
- 07/29/2021
|
CORT or ZTS: Which Is the Better Value Stock Right Now?
- CORT vs. ZTS: Which Stock Is the Better Value Option?
- 07/27/2021
|
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
- Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/22/2021
|
Dividend Challenger Highlights: Week Of July 18
- Dividend Challenger Highlights: Week Of July 18
- 07/17/2021
|
Moderna Pops, Zoetis Drops, and Stocks Are Higher
- Futures on all three major U.S. stock exchanges were higher as investors assess better-than-expected news about retail sales.
- 07/16/2021
|
After A 10% Rise In A Month Zoetis Stock May Continue To See Higher Levels
- The stock price of Zoetis, an animal health company, has seen a 10% rise over the last twenty-one trading days, while it is up 40% over the last year. ZTS stock has benefited from an increased animal adoption in the U.S., which aided its sales for parasiticide products for companion animals.
- 07/08/2021
|
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
- AMRX vs. ZTS: Which Stock Is the Better Value Option?
- 07/07/2021
|
Zoetis Donates COVID-19 Vaccines to Help Support the Health of Zoo Animals
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis is donating more than 11,000 doses of its experimental COVID-19 vaccine for animals to nearly 70 zoos across the U.S.
- 07/02/2021
|
Pandemic Boosts Animal Health Spending: 4 Stocks to Buy
- Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.
- 06/29/2021
|
Zoetis: The Price To Pay For A Leader In Animal Health
- There are positive industry-wide tailwinds for Animal Health as a niche segment of the broader pharmaceuticals industry. Being a leader in Animal Health, ZTS is poised for long-term outperformance due to its innovative ability and strategic position.
- 06/27/2021
|
Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?
- Zoetis stock has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck's stock has underperformed and gained only 26% of its value. Looking at valuation, Merck stock trades at about 4x trailing revenues, compared.
- 06/21/2021
|
Overview Of Opportunities In Animal Companionship: A $200B Industry Growing At 6.1% Annually
- The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets.
- 06/11/2021
|
Up 100% in a Year, Can This Animal Health Stock Keep Climbing?
- Not only has Heska stock doubled in a year, it has quintupled over the past five years, and it's a 20-bagger over the last decade. Why is this animal health stock flying so high?
- 06/09/2021
|
Zoetis to Participate in the William Blair 41st Annual Growth Stock Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #WilliamBlair--Zoetis Inc. will participate in the William Blair 41st Annual Growth Stock Conference on Wednesday, June 2, 2021.
- 05/27/2021
|
Zoetis Earns the Best Place To Work Certification in Thailand for 2021
- BANGKOK--(BUSINESS WIRE)-- #BPTW4Thailand--Zoetis Thailand, an affiliate of the global animal health company dedicated to supporting customers and their businesses in ever better ways, has recently been recognized as one of the best places to work in Thailand for 2021. During the assessment, the company received outstanding scores across several aspects of their workplace going above and beyond the norm to create an enjoyable and meaningful work environment. In this very unusual year, we learned again that empl
- 05/24/2021
|
Zoetis Announces Results of Its Annual Meeting of Shareholders; Board Declares Third Quarter 2021 Dividend
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #annualmeeting--Zoetis announced the results of shareholder voting at its 2021 Annual Meeting of Shareholders and provided details on its third quarter 2021 dividend.
- 05/20/2021
|
Growth Stock Spotlight: Acquisition Pits CSOC as Fresh Option in Booming Petcare Market
- While the market has taken a beating over recent days, pullbacks are the mother's milk of effective investment strategies, and shrewd market participants will already have a growing shopping list on hand. With that in mind, one area that may deserve special attention and offer outsized potential ahead is the pet care space.
- 05/13/2021
|
Boost Your Future Income With These Fast Growing Dividends
- Fast growing dividends may have low initial yields but will grow rapidly over time.
- 05/12/2021
|
AMRX or ZTS: Which Is the Better Value Stock Right Now?
- AMRX vs. ZTS: Which Stock Is the Better Value Option?
- 05/10/2021
|
Zoetis (ZTS) Just Overtook the 20-Day Moving Average
- When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
- 05/10/2021
|
Zoetis: 3.7% Dip Despite Strong Q1 And Raised 2021 Outlook
- Zoetis stock fell 3.7% on Thursday despite stronger-than-expected Q1 results and a raised 2021 outlook, including Net Income growing 12-14%. In Q1, Zoetis revenues grew 21%, led by Companion Animals up 34% but with Livestock up 17% in International; Net Income grew 34%.
- 05/07/2021
|
Zoetis CEO discusses growth opportunities
- Kristin Peck, Zoetis CEO, joins 'Closing Bell' to discuss growth opportunities at the company.
- 05/06/2021
|
Zoetis Inc. (ZTS) CEO Kristin Peck on Q1 2021 Results - Earnings Call Transcript
- Zoetis Inc. (ZTS) CEO Kristin Peck on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- 04/22/2021
|
8 Retirement Stocks to Buy for Any Market Conditions
- 2020 shows that investors need to be prepared for anything. These eight retirement stocks can do precisely that.
- 04/06/2021
|
Steven Cohen Adopts Stake in Kindred Biosciences
- Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 9.31% stake in Kindred Biosciences Inc. (NASDAQ:KIN) earlier this week.
- 04/02/2021
|
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
- USNA vs. ZTS: Which Stock Is the Better Value Option?
- 03/17/2021
|
Why Zoetis Is the Pfizer of Animal Healthcare
- Zoetis has proven to investors that the pharmaceutical apple doesn't fall far from the tree.
- 03/16/2021
|
Zoetis: Multi-Year Compounder On Sale Again After 14% Correction
- We upgrade Zoetis to Buy after a 14% price decline, means this multi-year compounder once again offers a low-teens annualized return.
- 03/15/2021
|
Is Zoetis Still a Buy With Its Stock Near All-Time Highs?
- This leader in animal healthcare has shown strong financial performance through the years.
- 03/13/2021
|
Will Zoetis' Acquisition Spree Pay Off?
- The animal health leader continues to invest in its future.
- 03/13/2021
|
Zoetis Launches “Driven to Care” Sustainability Initiative and Long-Term Goals to Meet Commitments to Communities, Animals and the Planet
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis today announced its long-term sustainability goals.
- 03/10/2021
|
Tuesday Morning Market Highlights
|
BofA Upgrades Zoetis Stock On Business Potential, Valuation
- Zoetis Inc (NYSE: ZTS) seems well-positioned in 2021 with the stock valuation offering an attractive entry point, according to BofA Securities. The Zoetis Analyst: Michael Ryskin upgraded the rating for Zoetis from Neutral to Buy, while maintaining a price target of $180.
- 03/08/2021
|
USNA or ZTS: Which Is the Better Value Stock Right Now?
- USNA vs. ZTS: Which Stock Is the Better Value Option?
- 03/01/2021
|
The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More
- Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.
- 02/28/2021
|
2 Fundamentally Superior Stocks I Just Rang the Register On
- When it comes to stocks to buy, we are getting more selective, and that's a good thing. In fact, buying pressure in more selective stocks means they may have more profit potential going forward.
- 02/23/2021
|
Zoetis' Solensia Wins European Nod For Osteoarthritis Pain In Cats
- Animal health company Zoetis Inc (NYSE: ZTS) received the European Commission's marketing approval for Solensia (frunevetmab), an injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats. Solensia targets Nerve Growth Factor (NGF), a key player in osteoarthritis pain.
- 02/22/2021
|
Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain
- ZAVENTEM, Belgium--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis receives European Commission marketing authorization for Solensia® (frunevetmab), a new therapy for feline osteoarthritis pain.
- 02/22/2021
|
Pet adoption theme will continue, says petcare company Zoetis' CEO
- Pet care company Zoetis beat on the top and bottom lines after reporting earnings this morning. The company is seeing strong momentum for 2021, despite pandemic uncertainty.
- 02/16/2021
|
Zoetis says its revenue jumped 8% in the fiscal fourth quarter
- Zoetis Inc. (NYSE: ZTS) said on Tuesday that its revenue in the fiscal fourth quarter saw an 8% annualised growth to £1.29 billion. Its net income in Q4 stood at £258.21 million that translates to 53.94 pence per diluted share.
- 02/16/2021
|
Zoetis' (ZTS) CEO Kristin Peck on Q4 2020 Results - Earnings Call Transcript
- Zoetis' (ZTS) CEO Kristin Peck on Q4 2020 Results - Earnings Call Transcript
- 02/16/2021
|
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
- Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.
- 02/16/2021
|
Zoetis Earnings Top, Guidance Strong; ZTS Stock Rises
- Zoetis earnings and sales were better than expected, while the animal drug giant guided high for 2021. ZTS stock rose early Tuesday.
- 02/16/2021
|
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
- Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/12/2021
|
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
- Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.
- 02/11/2021
|
Zoetis Declares Second Quarter 2021 Dividend
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #dividend--Zoetis declares Q2'21 dividend.
- 02/10/2021
|
Earnings Preview: Zoetis (ZTS) Q4 Earnings Expected to Decline
- Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/09/2021
|
Forbes Names Zoetis One of America's Best Midsize Employers
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Forbes--Zoetis has been named one of America's Best Midsize Employers by Forbes Magazine for the fifth time.
- 02/09/2021
|
GRFS vs. ZTS: Which Stock Is the Better Value Option?
- GRFS vs. ZTS: Which Stock Is the Better Value Option?
- 02/03/2021
|
Believe It or Not, There's Something to See With Zomedica
- There's a lot of hype around ZOM stock these days, but the name could prove to be a growth star among pet-related equities. The post Believe It or Not, There's Something to See With Zomedica appeared first on InvestorPlace.
- 01/28/2021
|
Zoetis Scores 100% on 2021 Corporate Equality Index
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #LGBTQ--Zoetis named a best place to work for LGBTQ equality.
- 01/28/2021
|
ZOM Stock: Why Zomedica Shares Are on the Move Again Today
- Zomedica shares are surging after the company updated investors on a warrant-redemption cash influx and news that its end-of-March product rollout is on track. Pet-related stocks are hot and ZOM may be on the verge of a significant breakout.
- 01/19/2021
|
9 Hot Stocks to Buy Now to Profit off Chinese Markets
- These are some of the top stocks to buy if you want to make a play on the growth and strength of the Chinese economy. The post 9 Hot Stocks to Buy Now to Profit off Chinese Markets appeared first on InvestorPlace.
- 01/15/2021
|
The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader (Podcast Transcript)
- Welcome to Alpha Trader. We have a special double bill today in honor of wildcard weekend coming up on the show. Eddy Elfenbein of Crossing Wall Street giving us his top five new stocks for 2021. But first we are pleased to welcome back to the show, Ryan Detrick. He is Chief Market Strategist for LPL Financial. Ryan, welcome back to Alpha Trader.
- 01/14/2021
|
2 Dividend Increases To Consider
- Both stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average and median increase of 15.13%.
- 01/14/2021
|
Families are adopting, spending more on pets amid pandemic: Zoetis CEO
- Shelters have seen pet adoptions increase 15% year over year. As Americans spend more time at home with their companions, it has led to more spending on pet care, animal pharmaceuticals provider Zoetis CEO Kristin Peck explained.
- 01/13/2021
|
Growth In Pet Spending Is Off The Leash, Here Is How To Profit From It
- Rising pet ownership rates and a steadily increasing average household spending provide a powerful tailwind to this investment theme. Pet food, animal health, veterinary equipment, and specialized e-commerce are all fields prone to profit from the secular growth trend.
- 01/12/2021
|
GRFS or ZTS: Which Is the Better Value Stock Right Now?
- GRFS vs. ZTS: Which Stock Is the Better Value Option?
- 01/12/2021
|
The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader
- This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher speaking with LPL Financial's Ryan Detrick and Eddy Elfenbein, editor of the Crossing Wall Street blog and portfolio manager of the AdvisorShares Focused Equity ETF (CWS).
- 01/12/2021
|
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2020 Financial Results
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis will report Q4 and full year 2020 financial results on Tuesday, Feb 16, 2021.
- 12/30/2020
|
8 Pet Stocks That Will Make You Purr
- Americans love their pets, and no pandemic, not even the novel coronavirus, will change that, bolstering these eight pet stocks. The post 8 Pet Stocks That Will Make You Purr appeared first on InvestorPlace.
- 12/23/2020
|
5 Rational Biotech Stocks to Buy
- These biotech stocks allow you to profit off the innovations that are giving us longer, healthier lives through the companies that make them. The post 5 Rational Biotech Stocks to Buy appeared first on InvestorPlace.
- 12/22/2020
|
7 Healthcare Stocks to Buy With the Sector Under Scrutiny
- True, there are political risks in the industry. But there are also lots of growth opportunities for investors in healthcare stocks.
- 12/21/2020
|
Zoetis to Participate in the 39th Annual J.P. Morgan Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #JPM2021--Zoetis to present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021.
- 12/18/2020
|
Strong Fundamentals In The Animal Health Industry Will Drive Zoetis Shares To $200 And Beyond
- ZTS is the leader in the animal healthcare space, providing a multitude of products/services to customers. The company continues to have impressive earnings, even during the COVID pandemic and the management team is top tier.
- 12/11/2020
|
Zoetis Declares First Quarter 2021 Dividend; Board Approves 25% Payment Increase
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis declares Q1'21 dividend: Board approves 25% increase.
- 12/09/2020
|
Zoetis Appoints Tonie Leatherberry to Its Board of Directors
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis appoints Antoinette (Tonie) Leatherberry to its Board of Directors.
- 12/08/2020
|
Zoetis (ZTS) Down 7.6% Since Last Earnings Report: Can It Rebound?
- Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
- 12/05/2020
|
85 Million & Climbing: Why Pets = Profits for These 6 Companies
- More households own pets than have children, and they'll pay to keep their furry friends happy. Here are 6 big pet stocks.
- 12/03/2020
|
Zoetis Named One of the “Top 75 Companies for Executive Women” by Working Mother Media
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DiversityandInclusion--For the third year in a row, Zoetis has been named one of the "Top 75 Companies for Executive Women" by Working Mother Media.
- 12/01/2020
|
7 Pharmaceutical Stocks to Buy for 2021 and Beyond
- Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.
- 11/17/2020
|
Zoetis Inc.'s (ZTS) CEO Kristin Peck on Q3 2020 Results - Earnings Call Transcript
- Zoetis Inc.'s (ZTS) CEO Kristin Peck on Q3 2020 Results - Earnings Call Transcript
- 11/06/2020
|
Pet adoption demand drives strong Q3 earnings for Zoetis
- Zoetis, the largest global animal health company, reported third quarter earnings results. The CEO of Zoetis Kristin Peck, says she sees long-term trends where people tend more to their pets even after the pandemic is over.
- 11/05/2020
|
Zoetis Earnings, Sales Top Expectations; Animal Health Giant Hikes Guidance
- Zoetis earnings beat views and the animal health giant hiked its guidance. Zoetis stock was little changed after spiking to a record high Wednesday.
- 11/05/2020
|
Zoetis to Participate in the Credit Suisse 2020 Virtual Healthcare Conference
- PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to participate in the Credit Suisse Virtual Healthcare Conference on Nov. 10.
- 10/26/2020
|
